Work

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

Year: 2025

Type: article

Abstract: ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid‐refractory PL‐like eruptions, and may allow for continuation of ICI treatment.

Source: JEADV Clinical Practice

DOI: 10.1002/jvc2.70221

Authors: Evangelos Christou, Sharon Edwards, Andrew Affleck

Institutions: University of Dundee, King's College London, Ninewells Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,310